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Abstract
Background: Despite progress that has been made in the treatment of many immune-mediated inflammatory
diseases (IMIDs), there remains a need for improved treatments. Randomised controlled trials (RCTs) provide the
highest form of evidence on the effectiveness of a potential new treatment regimen, but they are extremely
expensive and time consuming to conduct. Consequently, much focus has been given in recent years to innovative
design and analysis methods that could improve the efficiency of RCTs. In this article, we review the current use
and future potential of these methods within the context of IMID trials.
Methods: We provide a review of several innovative methods that would provide utility in IMID research. These
include novel study designs (adaptive trials, Sequential Multi-Assignment Randomised Trials, basket, and umbrella
trials) and data analysis methodologies (augmented analyses of composite responder endpoints, using high-
dimensional biomarker information to stratify patients, and emulation of RCTs from routinely collected data). IMID
trials are now well-placed to embrace innovative methods. For example, well-developed statistical frameworks for
adaptive trial design are ready for implementation, whilst the growing availability of historical datasets makes the
use of Bayesian methods particularly applicable.
To assess whether and how these innovative methods have been used in practice, we conducted a review via
PubMed of clinical trials pertaining to any of 51 IMIDs that were published between 2018 and 20 in five high
impact factor clinical journals.
Results: Amongst 97 articles included in the review, 19 (19.6%) used an innovative design method, but most of
these were relatively straightforward examples of innovative approaches. Only two (2.1%) reported the use of
evidence from routinely collected data, cohorts, or biobanks. Eight (9.2%) collected high-dimensional data.
Conclusions: Application of innovative statistical methodology to IMID trials has the potential to greatly improve
efficiency, to generalise and extrapolate trial results, and to further personalise treatment strategies. Currently, such
methods are infrequently utilised in practice. New research is required to ensure that IMID trials can benefit from
the most suitable methods.
Keywords: Adaptive design, Basket design, Bayesian design, Composite endpoint, High-dimensional data, Routinely
collected data, SMART trial, Umbrella design
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Background
Immune-mediated inflammatory diseases (IMIDs)
consist of many distinct conditions that share com-
mon inflammatory pathways. They range in preva-
lence from more common conditions such as
rheumatoid arthritis (0.5–1% prevalence in western
populations [1]) and psoriasis (2% prevalence in
North America [2]), to much rarer conditions such
as Behçet’s disease (estimated 0.005% prevalence in
the US [3]). Overall, around 5–7% of the population
of western societies has at least one IMID [4], with
co-occurrence of multiple IMIDs common [5].
IMIDs are associated with significant, chronic, mor-
bidity affecting quality of life and leading to prema-
ture death. As many IMIDs develop later in life, the
prevalence is likely to increase as the world popula-
tion ages.
Despite substantial progress in treatment of IMIDs with
newly developed disease-modifying anti-rheumatic drugs
and biologics, a substantial proportion of patients fail to
respond to treatment or eventually relapse after successful
treatment [6]. Consequently, a considerable number of
new drugs are in the clinical development pipeline [7] that
require demonstration of efficacy and safety. Additionally,
with the number of treatments currently available, there is
substantial scope for optimising present use through the
development of ‘treat-to-target’ approaches [8] and the
tailoring of treatment according to patient subgroups [9].
Any such optimised approach also requires demonstration
of efficacy and safety, however.
The highest form of evidence is generated by ran-
domised controlled trials (RCTs). For a new drug they
provide the most compelling confirmation of benefit
over standard therapies. For comparing different
treatment optimization strategies, RCTs avoid biases
that may occur in an evaluation via a retrospective or
prospective observational study. Despite the benefits
of RCTs, there are important drawbacks too. RCTs
are very expensive to conduct, especially large phase
III trials with longer-term follow-up [10]. Accordingly,
there has been a strong focus on developing innova-
tive methods for increasing the efficiency of clinical
trials. These may have the aim of providing more in-
formation from the same number of patients (e.g., by
increasing the power to find significant treatment ef-
fects), or to reduce the average number of patients
recruited to trials without sacrificing power.
In this paper we provide an overview of several in-
novative methods for increasing the efficiency of clin-
ical trials, framing our discussions within the context
of potential benefits to IMID research. We also
present a review of recently published IMID trials to
investigate how often these approaches have been
used in practice.
Overview of innovative methods for immune-
mediated inflammatory disease trials
Emulating trials from observational data
Given the large costs associated with prospective RCTs,
an important question to consider is whether one is
needed to answer a research hypothesis. This question
has received particular attention in recent years, given
the increasing amount of routinely collected data avail-
able, from sources such as CALIBER [11]. Furthermore,
there are now an array of patient cohorts and registries,
with IMID-Bio-UK [12] an example of a UK initiative to
bring these together for various IMIDs.
These data sources allow comparisons of different treat-
ment strategies to be conducted through retrospective ob-
servational studies. Results from such analyses can be
valuable, but are subject to confounding and other flaws
such as selection bias and immortal-time bias [13]. This is
especially true if inappropriate analyses are applied.
An example, from outside of IMIDs, of where inappro-
priate analyses gave a misleading answer is presented by
Dickerman et al. [14]. The effect of statins on the risk of
developing cancer was assessed from retrospective data
by comparing individuals who had received multiple
years of statin therapy against those who had not. Even
after adjustment for potential confounders, this ap-
proach was severely biased: a consequence of the fact
that individuals who received multiple years of statin
therapy could not have done so if they had died from
cancer before or during that time. Within IMIDs, a re-
cent paper [15] reviewed retrospective comparative ef-
fectiveness evaluations in rheumatoid arthritis; it was
found most analyses had some flaws that would poten-
tially lead to biases.
Instead, an approach called emulation of a target trial
[16] can address many biases and result in more reliable
answers. This involves specifying the ‘target trial’ that
one would have liked to have done (i.e., which patient
population, intervention, comparator, and outcomes)
and analysing the data in a way that emulates this as
closely as possible. Each timepoint in the retrospective
data is then examined to identify which patients would
have been eligible for randomisation in the target trial.
The probability that they could have received interven-
tion or comparator is modelled in a way that emulates
random assignment from a trial as closely as possible.
Dickerman et al. [14] demonstrate how this approach,
applied to data from CALLIBER, yields the same conclu-
sions as a large meta-analysis of RCTs for the (lack of)
effect of statins on reducing risk of cancer.
With many IMIDs being chronic conditions, RCTs are
often used to compare different strategies for employing
treatments known to be efficacious. Examples may in-
clude testing different ‘treat-to-target’ strategies [8] that
may employ more aggressive treatment until a measure
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of disease activity is below a set threshold. When differ-
ent strategies are already being employed in practice,
and frequent measures of disease activity are recorded in
routine data, emulation of target trials may be an effi-
cient approach for evaluating different strategies.
It is important to note, however, that target trial emu-
lation is still subject to bias. This is especially true if the
routine dataset does not record sufficient information on
potential confounding variables (or if there is a lot of
missing data). Consequently, there may still be a need
for prospective RCTs of treatment strategies. Nonethe-
less, target trial emulation could play an important role
in prioritising which strategies should be tested and
whether an RCT is likely to be successful in finding a
significant effect.
Adaptive trial designs
An adaptive design is one “that offers pre-planned op-
portunities to use accumulating trial data to modify as-
pects of an ongoing trial while preserving the validity
and integrity of that trial” [17]. Adaptive designs consist
of a wide range of approaches that can improve effi-
ciency in trials. Unlike the other innovative methodolo-
gies we discuss here, they have been discussed at length
in other recent articles. There are both papers that have
provided an overview of adaptive designs in general [18]
and for specific clinical areas such as rheumatology [19].
We refer the reader to these articles for a comprehen-
sion introduction to adaptive designs.
However, we do provide in Table 1 a brief summary of
several available types of adaptation and their potential
advantages. We also highlight one key factor that influ-
ences the added efficiency provided by an adaptive de-
sign: the ratio between the recruitment length of the
trial and the time taken to observe the primary endpoint
[20]. If it takes a long time to observe the primary end-
point, then at an interim analysis there will be a propor-
tion of patients who do not contribute information and
who don’t benefit from an adaption. As an example, if
the primary outcome takes 1 year to observe and all pa-
tients are recruited in 6 months, then by the time the
first patient’s one-year outcome has been observed, all
patients have been recruited and the adaptive design
cannot provide any utility. A more quickly observed
‘intermediate’ outcome can be used to make adaptations,
but it must be sufficiently informative for the primary
outcome to be useful.
Given the amount of well-developed methodology now
available for adaptive trial design, it is this consideration
on the choice of primary outcome and its observation
time relative to the anticipated recruitment rate, which
we believe may principally influence whether an adaptive
approach would provide efficiency advantages for a given
IMID trial.
Basket and umbrella trial designs
Because of rapid advancements in biological and gen-
omic understanding during the past few decades, an in-
creasing number of new therapies are being formulated
to target specific molecular or immune aberrations.
Given that many IMIDs share common mechanisms,
these targeted therapies may perform equally well for
multiple distinct IMIDs.
Originating in oncology settings, basket and umbrella
trial designs have recently emerged as new types of effi-
cient approaches for testing treatment efficacy in poten-
tially heterogeneous subgroups [21]. These novel designs
are administratively efficient as they investigate multiple
treatments or diseases, sometimes both, in a single study
under an overarching protocol. Figure 1 gives conceptual






Allows a trial to be stopped early for efficacy, futility, or safety, when
there is enough evidence to justify doing so.
On average, the sample size that would be required by





Allows the treatment allocation ratio(s) to be altered as the trial
progresses.
Allocation can be skewed in favour of the treatment arm
that appears to have higher efficacy; meaning more
patients are expected to respond in the trial.
Multi-arm multi-
stage (MAMS)
Allows multiple treatments to be evaluated in a single trial. Interim
analyses allow less promising treatments to be removed from the trial
early.




Allows the sample size to be modified in response to the outcome
variation or treatment effect observed in the interim.
The trial is more likely to be powered at the desired




Allows the trial’s population to be adjusted to avoid enrolling patients
who don’t benefit from a treatment; typically this involves incorporating
information from, or adapting on, a biomarker.
Patient subgroups who will benefit most from particular
treatments can be identified and prioritized.
Platform trial Allows treatments to be added in to an ongoing trial. Typically involves
several treatments being evaluated under an overarching protocol.
Efficient for evaluating multiple treatments as new ones
become available over time.
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illustrations of basket and umbrella trial designs with
components (sub-studies) defined by biomarkers or gen-
etic mutations, to which the new treatment(s) for evalu-
ation are matched.
While traditional oncology trials focus on a single treat-
ment for a specific cancer histology, basket trials can in-
volve multiple histologies and enrol patients with a
common mutation that the new therapy targets. As shown
in Fig. 1, an oncology basket trial consists of a number of
sub-studies, with each specific to a histology or disease
subtype. The prinical aim is to test the treatment efficacy
in various sub-studies simultaneously. As examples, Dri-
lon et al. [22] evaluated the efficacy of Larotrectinib, a
tropomyosin receptor kinase inhibitor, in diverse TRK fu-
sion positive tumours. Hyman et al. [23] evaluated the
BRAF inhibitor vemurafenib, finding significant activity in
some tumours (e.g., non-small cell lung carcinoma (NSCL
C) and Erdheim-Chester disease), yet inactivity in pancre-
atic cancer and multiple myeloma.
Efforts have been made to translate the idea of basket
designs to disease areas outside of oncology. For ex-
ample, patients can be stratified to enter a trial with
Fig. 1 Illustrations of umbrella and basket trial designs, with the sub-studies evaluating the new treatment(s) that are matched by the pre-defined
biomarker(s) or genetic mutation(s)
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multiple sub-studies by biological characteristics, such as
disease stage, number of prior therapies, specific gen-
etic/epigenetic changes, or demographic characteristics
[24]. There is also precedent for a basket-type approach
having been used in IMID research. Although not offi-
cially labelled a basket trial, TRANSREG [25] is a multi-
centre open-label trial involving 11 IMID patient
subgroups evaluating the safety, biological and clinical
effects of low-dose interleukin-2. The broad eligibility
criteria allow patients with rare IMID diseases to partici-
pate in the trial.
Early strategies for analysing basket trials regard the
sub-studies in isolation. Although this fully acknowl-
edges the heterogeneity between responses to the same
treatment observed in the various patient subgroups, this
inevitably leads to low-powered tests due to small sam-
ple sizes. Several sophisticated approaches have been de-
veloped to enable sharing of information across sub-
studies [26–29], among which the proposal by Zheng
and Wason [26] can be readily applied to non-oncology
basket trials with covariates. With necessary extension
or modification, these approaches could lead to the effi-
cient design and analysis of IMID basket trials.
By contrast, umbrella designs, illustrated in Fig. 1, offer
the possibility to efficiently test multiple targeted therap-
ies in a single disease population [24]. To date, umbrella
designs have only been implemented in oncology [30]:
patients of the same tumour type, as screened by an
array of biomarkers, receive the treatment specific to
their genetic aberration. The ongoing ALCHEMIST trial
[31] represents an early example of an umbrella trial. It
enrols NSCLC patients and evaluates therapies targeting
two types of genetic changes, EGFR mutations and ALK
translocations, which are hypothesised as key factors to
tumour growth and disease progression.
The increased understanding in pharmacogenomics
and pharmacogenetics of IMIDs, especially rheumatoid
arthritis [9, 32], makes umbrella designs a suitable ap-
proach to answering more treatment-related questions
efficiently in a single trial. The identification of specific
genes and epigenetic changes involved in the develop-
ment of rheumatoid arthritis, which may be predictive of
the response to treatment, could potentially lead to the
initiation of an umbrella trial.
With the multi-biomarker approach of umbrella trials,
more patients are likely to meet eligibility criteria for at
least one of the biomarker-defined subgroups. This is
particularly beneficial compared to an alternative ‘en-
richment’ trial that tests one targeted treatment in a sub-
group. However, there are unresolved issues in how best
to allocate patients who test positive for more than one
biomarker, or to no biomarker, in an umbrella trial. Al-
locating the most suitable treatment to such patients is
not straightforward.
Umbrella designs are flexible and can possibly be inte-
grated with various adaptive designs to make them more
efficient. Biomarker adaptive randomization could be in-
corporated to assign patients to the most promising
biomarker-linked treatments using accruing trial data
(e.g., as in the recent BATTLE trials [33]); a MAMS type
approach could be used when a number of treatments
are available for evaluation within a cohort; and if prom-
ising treatments unavailable at the start of the trial be-
come available, protocol amendments could be made to
allow addition of trial arms.
Ultimately, both basket and umbrella designs allow in-
vestigators to test more research questions in the same
trial. Basket trials help assess whether a new therapy
works in distinct patient subgroups (or related diseases)
and to what extent [34], while umbrella trials identify
whether biomarker-treatment pairs are valid and which
one(s) can best improve outcomes.
Sequential multiple assignment randomised trial (SMART)
designs
Therapy of chronic conditions or rapidly fatal diseases
often requires several lines of treatment with different
drugs or interventions used as the disease progresses. In
each line, the treatment may achieve the required clin-
ical objective (e.g., response), or not (e.g., non-response).
When treatment fails for a patient at a certain line, it is
common medical practice to switch to a different treat-
ment or strategy for the next line. The type or dose of
the treatment/intervention may be adjusted repeatedly
according to a patient’s ongoing clinical information, in-
cluding their treatment history and response to previous
treatments [35, 36].
An adaptive intervention is a treatment strategy that
personalises treatment through established decision rules
that recommend when and how the treatment changes,
taking into account the history of previous treatments
and response to those treatments [37]. A Sequential
Multiple Assignment Randomised Trial (SMART) is a
multistage trial design that is used to construct effective
dynamic treatment regimens (DTR), also known as
adaptive interventions (AIs) or adaptive treatment strat-
egies [38]. Figure 2 depicts an example of a SMART de-
sign in which only non-responders to first stage
intervention are re-randomised in the second stage. This
would provide information to inform an AI that chooses
which first-line intervention to use, and how to subse-
quently treat patients who do not respond to the first-
line treatment.
An AI consists of four key elements: critical decision
point(s), intervention component(s), tailoring variable(s),
and decision rule(s). The first element, a sequence of crit-
ical decision point(s), comprises the intervention to begin
with, when and how to measure signs of response/
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nonresponse, how to maintain the success of the initial
intervention, and what interventions may be used for non-
responders. The second element, the intervention compo-
nents, is a set of intervention/treatment options at each
critical decision point. From Fig. 2 we can see that there
are two treatments options in the first stage (treatment A
and B), and six treatment options in the second stage (two
options for responders, and four options for no-
responders). The third element is the tailoring variable(s).
A tailoring variable is an early indicator of the overall out-
come (success or failure of the intervention). The response
status at week 24 plays the role of the tailoring variable in
the example shown in Fig. 2. Lastly, the decision rules oc-
curring at each critical decision point link the tailoring
variable(s) to the intervention components. Each stage in
a SMART corresponds to one of the critical decisions in-
volved in the adaptive intervention. Each participant
moves through the multiple stages, and at each stage the
participant is randomly (re) assigned to one of several
intervention options [35, 39]. Each AI can be summarized
in the form (X1;X2:X3) where X1 is the recommended
first-stage treatment, X2 the recommended second-
stage treatment for responders, and X3 the recom-
mended second-stage treatment for non-responders.
There are four different adaptive interventions em-
bedded in the SMART depicted in Figure 2: (A,A,C),
(A,A,D),(B,B,E), and (B,B,F).
SMARTs have been used for a wide range of chronic
conditions, including some IMIDs. Recent studies that
have used them include the CATIE study of treatments
for schizophrenia [40], the EXTEND trial of treatments
for alcohol dependence [41], and studies of treatments
for metastatic renal cell carcinoma [42], depression [43],
HIV infection [44, 45], ulcerative colitis [46], autoinflam-
matory recurrent fever syndromes [47], psoriasis [48–
50], and rheumatoid arthritis [51].
An alternative design to a SMART study is the use of
“multiple one-stage-at-a-time” randomised trials. This
design considers each critical decision point as an inde-
pendent trial [39]. For instance, from the SMART in Fig-
ure 2, there are three different “one-stage-at-a-time”
trials. The first trial would correspond to the first stage
treatment options. The second trial would study treat-
ment in non-responders to treatment A, and the third
trial would study treatment in non-responders to treat-
ment B. One advantage of the SMART design over the
“multiple one-stage-at-a-time” is that it uses information
from all stages to find the best AI. To do this, it uses Q-
Learning; a multistage regression method that can use
data from a SMART study to examine whether and how
certain variables are suitable to develop an AI or im-
prove an existing one [52, 53].
SMARTs are not without limitation, however. In par-
ticular, some issues arise from modelling data from
SMARTs when the estimation of the optimal AI is of
interest. These include model building, missing data,
statistical inference, and choosing an outcome when
only non-responders are re-randomised [36]. The fact
Fig. 2 An example SMART design. Only non-responders to the initial treatment are re-randomised in the second stage. R = randomisation
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that the re-randomisation depends on the evolving pa-
tient status, along with the sequential design nature of
the SMART, bring more complexities to the handling of
missing data compared to classical clinical trials. For in-
stance, in a SMART study where only non-responders
are re-randomised at the second stage, a patient who is
lost to follow-up during the first stage will have missing
information on their intermediate response status, sec-
ond stage treatment, and outcome. It is not possible to
know whether the information in the second stage is
truly missing or is missing by design since it depends on
an unobserved patient response status. Furthermore, the
use of flexible regression approaches to avoid complex
functions in the Q-learning approach can also make it
difficult to acquire interpretable results and valid statis-
tical inference due to potential high variability [36].
SMARTs provide a lot of potential utility to chronic
IMIDs, where the most suitable AI is of interest.
Use of high-dimensional data to stratify patients:
adaptive signature trial designs
It is common in clinical trials that only a subgroup of
treated patients may benefit from an experimental therapy
[54–57]. Identifying these subgroups would allow tailoring
of treatment, avoiding costly or toxic treatment of individ-
uals who will not benefit. To identify such subgroups, pre-
dictive biomarkers are required. Predictive biomarkers are
biomarkers (objective characteristics associated with some
aspect of a patient’s function or health), measured at base-
line, that are associated with the response to treatment. If
a predictive biomarker has been identified, this can be
used to predict the likely response to treatment. Some
clinical areas, such as oncology, have strong availability of
predictive biomarkers. For example, the RAS-mutation
identified a subgroup of patients with a significant benefit
across all efficacy endpoints associated with treatment for
colorectal cancer [58].
However, predictive biomarkers are lacking for most
IMIDs, meaning predicting response to treatment is
more difficult [59–61]. For example, in rheumatoid arth-
ritis although genetic variants associated with response
to methotrexate have been identified [62–65], there is a
lack of consensus on the predictive utility of these
variants.
In the absence of predictive biomarkers, alternative
methods that utilise high-dimensional information could
be used. With the rapid development of new next gener-
ation sequencing, proteomics, and medical imaging tech-
nologies, a large amount of high-dimensional data about
patients is starting to be collected in clinical trials. There
is the potential for this information to be informative for
identifying subgroups of patients who are likely to bene-
fit from a new treatment.
To utilize high-dimensional information in RCTs, a
method has been developed known as the adaptive sig-
nature design (ASD). The aim of the ASD is to allow a
single RCT to both test the overall treatment effect in all
patients and to form a predictive biomarker signature
that predicts a subgroup of patients who strongly benefit
from the treatment. Although the ASD has ‘adaptive’ in
its name, it is not actually an adaptive design as it does
not change anything about the trial.
The original method [66, 67] utilised (high-dimen-
sional) gene expression data in an oncology setting,
but it can be used in any case where heterogeneity in
the treatment effect is expected and there is high-
dimensional information available. Which of the high-
dimensional data should be included in the signature
is determined by imposing a threshold on the signifi-
cance level, odds ratios, and number of biomarkers.
Further papers have proposed modifications of the
original ASD [68–70] to provide improved perform-
ance (in terms of correctly identifying a subgroup
who benefit from treatment). In these methods, the
high-dimensional data is used to form a signature
that is computed based on the interaction between
these data with the treatment. The adaptive signature
is represented by a single score for each patient. The
scores can then be utilised to divide the patients into
subgroups using a variety of clustering techniques, or
as covariates in the tests of association with the out-
come. The test for the overall comparison between
the arms can be performed by testing for the differ-
ence between the arms in the trial population (at the
significance level α1) and testing for the difference be-
tween the arms in the subgroup (at significance level
α2). The overall significance level of the trial is then
controlled at the α = α1 + α2 level (Fig. 3).
In conclusion, ASDs are a novel methodology that
can develop and validate predictive signatures in a
single trial. They have the potential to increase the ef-
ficiency of clinical trials by finding the group of pa-
tients benefiting from particular treatments. However,
when the clinical benefit for a subgroup is minimal, a
large sample size might be required to detect it with
sufficient power. Additionally, the performance of the
designs deteriorates if there are many covariates that
are not associated with patient benefit. To address
this issue, an additional pre-filtering of the covariates
might be required. This family of designs may also
benefit from exploring different methods of inter-
action of treatment with high dimensional covariates
[71, 72], and from considering multiple trial end-
points [73]. These considerations notwithstanding,
ASDs offer a potential route to identifying patient
subgroups that will benefit from treatment in IMIDs
for which predictive biomarkers are currently lacking.
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Composite responder endpoints and augmented analysis
methods
Clinical trials specify primary and secondary outcomes
that measure how patients respond to a treatment or
intervention. The primary outcome should be chosen
as a measurement that will be more favourable if the
treatment being tested is efficacious or effective. As
many IMIDs have complex manifestations and mul-
tiple symptoms, it can be difficult to specify a single
measurement as being the most important. For this
reason, it is common that primary outcomes in IMID
trials combine multiple relevant measurements into a
single composite outcome. A specific type of compos-
ite endpoint is a responder endpoint, which divides
patients into responders and non-responders based on
different measurements, or components. Some of
these components can be binary and others may be
whether continuous measurements are above a
threshold.
The standard method of analysis for composite re-
sponder endpoints is to treat them as binary variables
(responder or non-responder). The analysis then esti-
mates the proportion of patients who are responders
and whether there is a significant difference between
arms: this is done with a suitable binary method such as
Fisher’s exact test or logistic regression, amongst many
others.
Responder endpoints have the appealing property of
summarising very complex information into an easy-to-
interpret single quantity. This is also a limitation when
Fig. 3 Schematic representation of the adaptive signature design
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applying analysis methods that treat the outcome as bin-
ary: much information is discarded, especially from con-
tinuous components when dichotomising (see, e.g. [74,
75]) which can lead to a reduction in power [76].
Assuming that the responder endpoint is clinically
relevant, there are alternative ways of estimating the pro-
portion of patients who are responders. For endpoints
that define response based on a single continuous com-
ponent, methods were proposed in the 1990s to more
precisely estimate the proportion of responders [77, 78].
For composite responder endpoints that are a mixture of
continuous and binary components, the augmented bin-
ary method has been proposed to provide higher effi-
ciency. This was originally proposed for response criteria
endpoints used in phase II oncology trials [79] but has
since been extended to endpoints used in IMIDs such as
rheumatoid arthritis [80] and systemic lupus erythema-
tosus (SLE) [81]. The method has also been extended to
endpoints that are formed from the time until a compos-
ite event occurs [82] (e.g., time until relapse, where re-
lapse involves a continuous biomarker being above a
certain level), although further work in this area is
needed.
The augmented binary method requires no additional
data to be collected; it simply fits a more complex statis-
tical model to the data collected on the different compo-
nents and uses this model to estimate the difference
between arms in the proportion of responders (together
with a confidence interval and p-value). It has been
shown in various papers [80, 81, 83, 84] to provide large
gains in efficiency, equivalent to applying the traditional
binary analysis with a sample size of 30% or more
higher. The extent of the increase of efficiency depends
on to what extent the continuous component(s) distin-
guish between responders and non-responders [85].
A previous review [86] found that several IMID condi-
tions used composite responder outcomes. We show
some examples of these in Table 2.
Current use of innovative methods in immune-
mediated inflammatory disease trials
Review methods
To investigate the frequency with which innovative
methods have been used in IMID trials in recent years,
we searched PubMed on June 182,020. We restricted
our evaluation to clinical trial publications that have ap-
peared since 2018 in any of five high impact factor jour-
nals relevant to IMIDs (New Engl J Med, Lancet, Ann
Rheum Dis, Arthritis Rheumatol, J Am Acad Dermatol).
To provide a comprehensive evaluation, we included ar-
ticles containing any of 51 IMID disease terms. See the
Supplementary Materials for the search term. This
search returned 160 articles for review.
Each article was reviewed by JMSW to establish
whether it met the inclusion criteria: that the article was
a primary report of the results of a clinical trial




ASAS20 response • 20% improvement and≥ 10 units of change (on a 0–100 scale) in each of 3
domains
• No worsening of a similar amount in the fourth domain
• (Components are physical function, pain, inflammation and patient’s global
assessment)
Crohn’s disease Clinical remission • Crohn’s Disease Activity Index below a threshold (e.g., 150)
• No use of steroids or rescue treatment
Idiopathic arthritis-
associated uveitis
Best corrected visual acuity above
threshold and no light perception
• Best-corrected visual acuity, thresholds ≤20/50, ≤20/200
• No light perception
•Contribution of amblyopia, yes/no
Juvenile arthritis Response Improvement by 30% in at least 3 of:
• MD global assessment
• parent or patient global assessment
• functional ability
• number of joints with active arthritis
• number of joints with limited range of motion
• Erthrocyte Sedimentation Rate
Juvenile
dermatomyositis
Responder index • ≥4 point reduction from baseline in safety of estrogen in lupus national assessment
(SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score
• No worsening (increase of < 0.30 points from baseline) in physician’s global
assessment (PGA)
• No new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain
score or 2 new BILAG B organ domain scores compared with baseline
Nonalcoholic
steatohepatitis
Resolution of steatohepatitis without
fibrosis
• Improvement in NAS of two points
• No worsening of fibrosis
Sjogren’s syndrome Response • > 30% reduction in analog scales evaluating dryness, pain and fatigue
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conducted to evaluate the efficacy of one or more treat-
ments for one or more IMIDs. Retrospective trial ana-
lyses were thus excluded, as our focus was on how
innovative methods have been used in practice in the de-
sign and analysis of IMID trials. For each article deemed
eligible for inclusion, data was extracted by JMSW for
21 questions relating to the trial’s design and analysis,
and in particular the use of innovative methods (see
Supplementary Table 1). Owing to the objective nature
of the extraction questions, high reproducibility on
evaluation of inclusion and subsequent data extraction
was anticipated. Nonetheless, ten articles were randomly
chosen for duplicate review by MJG. The authors agreed
on inclusion for all ten articles. Agreement on extracted
data was 95%. See the Supplementary Materials for fur-
ther details.
Findings
Ninety-seven articles were deemed to be eligible for in-
clusion. A summary of the extracted data for these 97
articles is given in Table 3.
While more than 20 distinct conditions were evaluated
in the eligible trials, the plurality (31%) found were in
rheumatoid arthritis. Notable numbers were also found
in psoriatic arthritis, psoriasis, and SLE. The majority of
trials (75%) were funded and sponsored by industry.
Most (65%) eligible trials had two arms. Some rarer con-
ditions used single arm trials with no prospective control
arm. In other cases, more than two arms were included: in
most instances this was for industry-funded trials of a new
drug, with different doses or regimens included as distinct
arms. We did not identify any MAMS trials.
There was some reported use of innovative ap-
proaches (19.6%). These consisted predominantly of
group-sequential designs (or a futility analysis),
sample-size re-assessment, and re-randomising some
participants as in a SMART design. For re-
randomisations, we did not find any examples where
an analysis was performed to determine the best AI.
The median recruitment length was 96 weeks and pri-
mary endpoint length was 24 weeks. This indicates
that for a majority of trials the ratio of endpoint
length to recruitment length would be sufficiently low
for an adaptive design to provide efficiency [20].
In a majority of trials (60%), patients with other auto-
immune diseases were not eligible for the trial. In other
cases, this was not an explicit exclusion criteria but it is
likely that such patients would be indirectly excluded
through criteria such as being naïve to therapies that are
commonly used for other IMIDs.
We found very few examples where collection of high-
dimensional data was reported (8.2%). In the eight trials
that did report this, the most common approach was to
analyse each variable separately. Reported use of
routinely collected data in the design of the trial was also
low.
The use of responder endpoints (involving dichotomi-
zation of continuous measurements) was very high. The
majority of trials (68%) had a primary endpoint that was
defined in this way; an even higher proportion (84%) had
a responder endpoint as a secondary outcome. These
endpoints were routinely analyses using standard
methods, such as a Cochrane-Mantel-Haenszel or Fish-
er’s exact test.
Use of innovative methods in currently ongoing trials
There is often a long lead time between designing a trial
and it being reported. We therefore also conducted a
scoping review of use of innovative designs in trials that
are currently underway. We searched clinicaltrials.gov
on 2 February 2021 for studies that were ‘not yet recruit-
ing’, ‘recruiting’, ‘enrolling by invitation’, or ‘active, not
recruiting’ that contained any of 51 IMID disease terms
and any of 39 terms related to innovative design. A link
to conduct this search is given in the Supplementary
Materials. It returned 49 studies that were then reviewed
by MJG to evaluate evidence of innovative design use.
There were some examples of innovative designs being
used. This included multiple group-sequential and seam-
less phase II/III trials. We also found trials using a
Bayesian basket design (NCT04498962), MAMS design
(NCT03092674, NCT03805789) and several uses of
adaptive randomization (NCT04596293, NCT02269280,
NCT02593123). With limited details provided in trial
registrations compared to trial publications, it was not
possible to extract detailed information and we may well
have missed use of innovative approaches.
Discussion
In this paper we have provided an overview of innovative
methods that could provide utility to IMID trials. These
methods and their advantages are summarized in
Table 4. We have also shown that few recently reported
trials are utilizing innovative approaches through a lit-
erature review.
Although 19.6% of included trials used some approach
that we classified as innovative, most of these were rela-
tively straightforward approaches, such as a futility ana-
lysis or having a second randomization of non-
responding patients (without applying techniques for
analysing SMARTs.) Assessment of current IMID trials
listed on clinicaltrials.gov indicates that use of innovative
approaches may still be infrequent. There is a high po-
tential for more advanced innovative approaches to be
used in future IMID trials, but this requires improved
awareness, education, and software.
One notable finding was that it was very common,
amongst multiple distinct IMIDs, for trial endpoints to
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be responder endpoints. Over two-thirds of trials had
such an endpoint as the primary, and almost 90% had a
secondary endpoint. In every case the endpoint was ana-
lysed as if it were binary. As we have described, there
are much more efficient analysis methods available and
it is important for them to be made available for use in
practice. Some freely-available software is currently
available [87] but there is the need for more generic soft-
ware and methods that can be used across all such end-
points used in IMID trials.
Presently, it appears that collection of high dimen-
sional information and use of routinely collected data is
rare in IMID trials. A limitation of our review is that we
may have missed use of this from just examining
Table 3 Summary of extracted data for the 97 included articles.
The denominator for computing percentages (given to 1
decimal place) is 97 unless stated otherwise
Question n (%)
What immune-mediated inflammatory disease(s) was the trial conducted
in?a
Rheumatoid arthritis 30 (30.9)
Systemic lupus erythematosus 10 (10.3)
Psoriasis 9 (9.3)
Psoriatic arthritis 9 (9.3)
Juvenile idiopathic arthritis 4 (4.1)
Multiple sclerosis 4 (4.1)
Sjögren’s syndrome 3 (3.1)
Systemic sclerosis 3 (3.1)
Other (see Supplementary Materials) 25 (25.8)







What was the total planned sample size according to










Not reported 3 (3.1)
Charity 1 (1.0)
Was any innovative design used?b
Yes 19 (19.6)
Group-sequential design/futility interim analysis 7 (7.2)
Sequential multiple assignment randomised trial
design
6 (6.2)
Bayesian methods used 4 (4.1)
Sample size re-estimation 2 (2.1)
Basket trial design 1 (1.0)
Use of an innovative design by trial funding
Industry 16/73 (21.9)
Other 3/24 (12.5)
Did the trial design report the involvement of any evidence from
routinely collected data, cohorts, or biobanks?
Yes 2 (2.1)
What was the length of patient recruitment (in weeks)?c Median: 96
IQR: [55, 120]
Range: [16,
Table 3 Summary of extracted data for the 97 included articles.
The denominator for computing percentages (given to 1
decimal place) is 97 unless stated otherwise (Continued)
Question n (%)
296]




Did the exclusion criteria explicitly include the presence of another
autoimmune disease?e
Yes 58 (59.8)
Were any endpoints based on dichotomizing continuous information?
Primary 66 (68.0)
Secondary 81 (83.5)
How were dichotomized responder endpoints analysed?f
Cochrane-Mantel-Haenszel test 27 (27.8)
Logistic regression 21 (21.6)
Chi-square test 9 (9.3)
Cox model 9 (9.3)
Fisher’s exact test 9 (9.3)
Log rank 5 (5.2)
Other 16 (16.5)
Any high-dimensional data collected at baseline (gene expression,
GWAS, synovial biopsies etc.)?g
Yes 8 (8.2)
aA small number of articles included patients with more than one IMID in their
trial, though none for the diseases named here
bOne article used a sequential multiple assignment randomised trial design
with an interim futility assessment
cOne article did not report the recruitment period. To translate recruitment
periods given inmonths to weeks, 4 weeks was taken to be equivalent
to 1 month
dFor two, one, and one article respectively the median, mean, and maximum
follow-up times are used. To translate recruitment periods given in days and
months to weeks, 30 days and 1month were taken to be equivalent
to 4 weeks
eOne article reported “any serious illness” as an exclusion criteria and is
considered as ‘No’ for the extraction
fArticles may have utilised more than one method
gThree articles that collected MRI imaging data, for which it was unclear as to
whether this was high-dimensional, are listed as ‘No’ for the extraction
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primary reports of RCTs. For example it may be com-
mon for high-dimensional information to be collected
but reported in secondary analysis papers. In addition it
may not be felt a worthwhile use of space in a primary
report of an RCT to discuss how routinely collected data
was used to inform the trial design.
The majority of trials were sponsored and funded by
industry. Although there were uses of innovative ap-
proaches in industry sponsored trials, use of more ad-
vanced methods that we have discussed in this paper
could be hampered by regulatory issues (either actual or
perceived). For use of some more advanced designs and
analysis approaches in confirmatory trial settings, it will
be important to ensure they are supported by regulators.
A final important consideration for the potential applic-
ability of the discussed innovative methods is disease
prevalence. Some methods we have discussed are particu-
larly relevant in rare disease settings: 1) As composite end-
points are recommended for rare diseases, the augmented
analysis methods are more applicable [88]; 2) Basket trials
potentially allow borrowing of information, and may thus
improve analysis of related rare IMIDs (or for a rare IMID
to be tested in conjunction with a common IMID); 3)
adaptive designs may be more relevant in rare diseases
due to the need to improve efficiency [89] and can be used
in single-arm trials, such as the Simon two-stage design
[90] that is widely used in phase II cancer trials [91]. Other
approaches may not be so applicable in rare settings due
to the need for high sample sizes.
In conclusion, IMID trials could substantially benefit
from use of more innovative approaches that we have
reviewed in this paper. Further research, better software,
and more dissemination is needed to ensure all IMID
trials, that could benefit, do so.
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Table 4 Summary of innovative design and analysis approaches briefed in this paper
Innovative method Summary
Adaptive designs • Offer opportunity to make changes to the design of an ongoing trial as patient outcome data is accrued.
• Can improve efficiency of trial (more power for same sample size, or reduced sample size for same
power), make trial more robust to design assumptions, and/or improve patient benefit provided by trial.
• Benefit relies on the primary endpoint (or informative intermediate endpoint) being observed relatively
quickly compared to recruitment.
Adaptive signature design • Uses high-dimensional data to form a ‘sensitive’ subgroup of patients who experience higher benefit
from an intervention in comparison to the overall population.
• Allows forming, and confirmatory testing, of a predictive signature in the same trial.
• May be difficult to interpret the resulting signature.
Augmented analysis of composite
responder outcomes
• Efficiently analyse responder endpoints, which classify patients as responders or non-responders on the
basis of a combination of binary and continuous measurements.
• Can substantially improve the power of trials using responder endpoints whilst maintaining the clinically
relevant outcome.
• More complex analysis that makes extra assumptions compared to the traditional analysis approach.
Basket and umbrella designs • Use an overarching protocol to test interventions in related disease conditions or patient subgroups,
simultaneously.
• Allow operational and statistical efficiencies; with the latter realised by using advanced statistical
approaches that can e.g., share information between the different arms of the trial.
• Generally requires assuming the same endpoint and control group, despite various sub-studies, in the
trial.
Emulation of trials • A method for using large retrospective datasets to predict what it would have been if yielded by a
randomised controlled trial.
• Exploits the value of data that is already collected.
• Analysis makes strong assumptions and can only compare interventions in current use.
Sequential Multi Assignment
Randomised Trials (SMART)
• Allow multiple randomisations of patients at different stages of the study.
• Allow separate research questions to be answered and for the optimal ‘adaptive intervention’ to be
found.
• For a specific AI, they allow to improve individual outcomes by further tailoring treatment by baseline or
time-varying characteristics.
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